Indian stocks: Visit www.stage2stocks.com →

Sol-Gel Technologies Ltd.

Stage 4 · Declining · week 2

As of Oct 22, 2026, Sol-Gel Technologies is in Stage 4, the downtrend phase, now in week 2 (since Oct 13, 2026). It closed at $67.39, 31.2% below its 52-week high and below its 200-day average, which is rising.

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada,… More about the company

$67.39
+2.54% today
$221M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Accelerating ⇈

Edge

—

Is SLGL early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 48w
S2 47w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 1w → S4 48w → S1 1w → S4 11w → S1 5w → S4 6w → S1 2w → S2 8w → S3 2w → S4 6w → S1 5w → S2 47w → S3 10w → S2 8w → S3 4w → S4 1w current
Total tracked: 165 weeks across 16 stage runs.

SLGL among Biotechnology72nd of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…72SLGLStage 4 · wk 291+12.9%
vs 52W High
-31.2%
$30.64 lo$97.97 hi
31.2% below 52W high, ongoing decline
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 2
1w13w26w
Week 2, early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-8.7%
200 DMA: $73.77 · rising
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.87x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↑ ⇈
Short-term trend rising strongly, and accelerating
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+12.9%
3M
-17.8%
6M
-6.8%
YTD
+59.9%
1Y
+68.5%
Scan Membership
Breakout Watch
Latest: 2025-06-16
6 appearances in last 60 days. First seen: 2019-04-08.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 2 · Vol 0.87x
2026-10-21S4
Wk 2 · Vol 1.08x
2026-10-20S4
Wk 2 · Vol 0.83x
2026-10-19S4
Wk 1 · Vol 0.25x
2026-10-16S4
Wk 1 · Vol 1.27x
2026-10-15S4
Wk 1 · Vol 0.74x
2026-10-14S4
Wk 1 · Vol 0.48x
2026-10-13S43→4
Wk 1 · Vol 0.59x
2026-10-12S3
Wk 4 · Vol 0.50x
2026-10-09S3
Wk 4 · Vol 0.54x
2026-10-08S3
Wk 4 · Vol 0.70x
2026-10-07S3
Wk 4 · Vol 0.53x
Moving averages & range
50 DMA
$70.55
200 DMA
$73.77
52W High
$97.97
52W Low
$30.64
5D Low
$64.25
Resistance levels (recent highs)
20d High
$78.95
60d High
$88.00
120d High
$89.74
250d High
$97.97
Next resistance
+17.2%
to 20d High
ROE
-40.9%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 4.6

Sol-Gel Technologies: quick answers

What stage is Sol-Gel Technologies in?

As of Oct 22, 2026, Sol-Gel Technologies (SLGL) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 13, 2026 and is in week 2. What the four stages mean

Is Sol-Gel Technologies in an uptrend?

No. Sol-Gel Technologies is in a Stage 4 downtrend. It trades 8.7% below its 200-day average, which is rising.

How far is Sol-Gel Technologies from its 52-week high?

Sol-Gel Technologies closed at $67.39 on Oct 22, 2026, 31.2% below its 52-week high of $97.97. Its 52-week low is $30.64.

How has Sol-Gel Technologies performed over the past year?

As of Oct 22, 2026, Sol-Gel Technologies is up 68.5% over the past year and up 59.9% so far in 2026.

Which sector and industry is Sol-Gel Technologies in?

Sol-Gel Technologies is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.